Quantcast

Latest Menorrhagia Stories

2010-05-24 15:05:00

SAN DIEGO, May 24 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced statistically significant and clinically meaningful top-line efficacy results from its Phase II Daisy PETAL study (901 study) using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis. "The Daisy PETAL study was successful, all primary and secondary efficacy endpoints were met, and provided...

2010-05-19 08:00:00

SAN FRANCISCO, May 19 /PRNewswire/ -- Five presentations reporting the results of two placebo-controlled clinical trials evaluating Ferring Pharmaceuticals' LYSTEDA(TM) (tranexamic acid) tablets, a novel, first-in-class, non-hormonal therapy indicated for treatment of women with cyclic heavy menstrual bleeding (HMB), were presented at The American College of Obstetricians and Gynecologists 58th Annual Clinical Meeting in San Francisco, May 15-19, 2010. It is estimated that up to 22...

2010-05-18 07:30:00

NATICK, Mass., May 18 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) approval of its Genesys HTA(TM) System for the treatment of menorrhagia. The Genesys HTA System is a next-generation endometrial ablation system designed to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia. Menorrhagia is abnormally heavy and prolonged menstrual bleeding. An estimated 10 million women in the...

2010-05-11 09:30:00

BEDFORD, Mass., May 11 /PRNewswire-FirstCall/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today the availability of its next generation NovaSure(®) system -- a 90-second, minimally-invasive, outpatient treatment for women suffering from excessive menstrual bleeding. The...

2010-05-10 07:00:00

NEWPORT, Ky., May 10 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, today announced that it has tightly focused the strategic direction for the company on the pain management market. The company plans to leverage its core expertise in the prescription pain category by developing a range of products that address both the acute and chronic pain prescription segments as well as the over-the-counter pain market. Xanodyne has nearly a...

dd8bc982e7f4c28b0a33392f437294c21
2010-03-24 08:08:13

Scientists described yesterday the discovery of a new drug, which is currently in Phase II clinical trials, designed to specifically target the root cause of painful menstrual cramps, not just the symptoms. The condition, called dysmenorrhea, is the leading cause of absenteeism from school and work among women in their teens and 20s. The scientists described the study at the American Chemical Society (ACS) 239th National Meeting, being held this week. "We hope that the drug will provide a...

2010-02-09 10:00:00

PEORIA, Ariz., Feb. 9 /PRNewswire/ -- A leading clinical research center in Peoria has joined an international research program to study an investigational drug designed as a possible treatment for painful menstrual cramps, or dysmenorrhea, a condition that affects between 45 and 90 percent of women of childbearing age in the United States. Although not life threatening, dysmenorrhea can be debilitating and psychologically taxing and is one of the leading causes of absenteeism from work and...

2010-01-11 09:00:00

SALT LAKE CITY, Jan. 11 /PRNewswire/ -- A leading clinical research center in Salt Lake City has joined an international trial program to test an experimental new drug designed to treat painful menstrual cramps, or dysmenorrhea, a condition that affects between 45 and 90 percent of women of childbearing age in the United States. Although not life threatening, dysmenorrhea can be debilitating and psychologically taxing and is one of the leading causes of absenteeism from work and school....

2010-01-11 08:00:00

AUSTIN, Texas, Jan. 11 /PRNewswire/ -- A leading clinical research center in Austin has joined an international research program to study an investigational drug designed as a possible treatment for painful menstrual cramps, or dysmenorrhea, a condition that affects between 45 and 90 percent of women of childbearing age in the United States. Although not life threatening, dysmenorrhea can be debilitating and psychologically taxing, and is one of the leading causes of absenteeism from work...

2009-11-16 15:11:00

BEDFORD, Mass., Nov. 16 /PRNewswire-FirstCall/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, is participating in the 38(th) Annual American Association of Gynecologic Laparoscopists (AAGL) conference, November 15-19, 2009 in Orlando, Florida, and will feature its Adiana(®) permanent...


Word of the Day
ambsace
  • Bad luck; misfortune.
  • The smallest amount possible or the most worthless thing.
The word 'ambsace' comes from a Latin word meaning 'both'.